Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Buys Option For Vivet In Latest Gene Therapy Tie-Up

Executive Summary

The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.

You may also be interested in...



Interview: Pfizer's Smith On Building A Gene Therapy Business

Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Pfizer's Business Development Transition: From "Revenues Now" To Pipeline Development

Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124942

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel